Skip to main content

Adaptimmune Therapeutics Value Stock - Dividend - Research Selection

Adaptimmune therapeutics

ISIN: US00653A1079 , WKN: A14SUX

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune's PRIME technology. It also has a co-development and co-commercialization agreement with Universal Cells, Inc to bring new stem-cell derived allogeneic T-Cell therapies to people with cancer. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company

2024-06-12
By Michael Kim NASDAQ:ADAP READ THE FULL ADAP RESEARCH REPORT We are initiating coverage of Adaptimmune Therapeutics plc (NASDAQ:ADAP) with a 12-month price target of $3.00, translating into sizeable upside from the stock’s current price. Adaptimmune designs, develops, manufactures, and delivers innovative cell therapies via the company's unique T-cell receptor (TCR) platform to treat cancers

Adaptimmune Enhances Executive Severance and Benefit Terms

2024-06-11
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Adaptimmune Therapeutics (ADAP) Gets a Buy from TD Cowen

2024-06-04
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Buy Rating for Adaptimmune on Strong Partnership Potential and Financial Upside

2024-06-04
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Adaptimmune’s Strategic Collaboration with Galapagos: A Cautious Hold Amid Promising Developments

2024-06-04
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise

2024-06-03
Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysisInterim analysis data reinforces the potential of lete-cel to bolster Adaptimmune's sarcoma franchise by expanding addressable sarcoma patient populationFull results from the pivotal IGNYTE-ESO trial are expected in late 2024Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - June 3, 2024) - Adaptimmune Therapeutics plc

Biotech Alert: Searches spiking for these stocks today

2024-06-03
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session

2024-05-31
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

12 Health Care Stocks Moving In Friday's Pre-Market Session

2024-05-31
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Why Zscaler Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

2024-05-31
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.